The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Gilead Sciences (I)
Research Funding - Juno Therapeutics
Gastrostomy, tracheostomy, opioid, and health care utilization among patients with recurrent/metastatic head and neck cancer receiving immunotherapy.
 
Natalie F. Uy
No Relationships to Disclose
 
Kevin Ng
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Vicky Wu
No Relationships to Disclose
 
Neal D. Futran
Consulting or Advisory Role - Stryker
Travel, Accommodations, Expenses - Stryker
 
Jeffrey Houlton
Research Funding - Presage Biosciences
 
Brittany Barber
No Relationships to Disclose
 
George E. Laramore
No Relationships to Disclose
 
Upendra Parvathaneni
No Relationships to Disclose
 
Jay Justin Liao
No Relationships to Disclose
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Millenium Pharamceuticals (I)
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst)